Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02536352 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being
A Early Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 43
- Enrollment target
NCT02536352: Completed Early Phase 1 study, sponsored by Johns Hopkins University.
NCT02536352 is a Early Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 43 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02536352, a Early Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether fluoride supplementation during pregnancy is effective in extending the length of gestation and improving overall perinatal well-being.
Primary Outcome
the length of gestation will be measured in weeks at time of delivery
Interventions
- DRUG Prenatal vitamin-mineral containing 3 mg fluoride
- DIETARY_SUPPLEMENT Prenatal vitamin-mineral containing 0 mg fluoride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-10-01 |
| Phase | Early Phase 1 |
What the finished NCT02536352 record still lists
NCT02536352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 2 interventions - of which Prenatal vitamin-mineral containing 3 mg fluoride is the first listed.
NCT02536352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02536352 about?
NCT02536352 is a clinical study titled "Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being". The purpose of this study is to determine whether fluoride supplementation during pregnancy is effective in extending the length of gestation and improving overall perinatal well-being.
What is the current status of trial NCT02536352?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 43 participants. The study started on 2015-10. Estimated completion is 2019-10-01.
What interventions are being tested in trial NCT02536352?
The interventions under investigation include: Prenatal vitamin-mineral containing 3 mg fluoride (DRUG), Prenatal vitamin-mineral containing 0 mg fluoride (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02536352?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02536352's enrollment target sits among peer trials
43 600th of 2000 higher than 1,397 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia